US IPO Pipeline SEC S-1 Filings — July 15, 2026

15-07-2026

Vogenx, Inc. filed an S-1 registration statement with the SEC for an initial public offering of common stock on the Nasdaq Capital Market under the symbol 'VOGX'. The company has incurred significant operating losses, with net losses of $2.2M in FY2024, $1.4M in FY2025, and $475K in Q1 2026, and an accumulated deficit of $11.3M as of March 31, 2026. Proceeds from the offering will fund continued development of its drug candidate mizagliflozin and general corporate purposes.

• · Total operating expenses decreased from $2.3M in FY2024 to $1.4M in FY2025, but increased from $0.4M in Q1 2025 to $0.5M in Q1 2026.
• · Working capital deficit was approximately $1.4M as of March 31, 2026 (actual).
• · The company had only $251K in cash and cash equivalents as of March 31, 2026, indicating immediate need for IPO proceeds.
• · The offering is contingent on listing on the Nasdaq Capital Market.
• · 1,685,000 stock options outstanding with a weighted-average exercise price of $0.35 per share.
• · The company has restated its FY2024 and FY2025 financial statements to correct an error in net loss per share calculation.

15-07-2026

Braveheart Bio, Inc. filed an S-1 registration statement with the SEC on July 14, 2026, for an initial public offering of common stock to be listed on Nasdaq under the symbol 'BRVE'. The company is a clinical-stage biopharmaceutical company developing BHB-1893, a next-generation cardiac myosin inhibitor for hypertrophic cardiomyopathy, which it in-licensed from Jiangsu Hengrui Pharmaceuticals. While BHB-1893 showed promising Phase 2 results (86% complete response rate at Week 12 in oHCM), the company faces significant risks including reliance on a single product candidate, limited clinical data, and competition from approved CMIs mavacamten and aficamten which have shown only 49-57% complete response rates in pivotal trials.

• · Braveheart Bio is a clinical-stage company with no approved products and no prior public market for its stock.
• · BHB-1893 was initially discovered and developed by Hengrui in China; Braveheart was not involved in the design, conduct, or oversight of completed clinical trials.
• · The company has applied to list on Nasdaq under the symbol 'BRVE' and qualifies as an emerging growth company and smaller reporting company.
• · The offering is subject to SEC effectiveness and Nasdaq listing approval; the initial public offering price range is not yet disclosed.
• · Underwriters have been granted an option to purchase up to an additional number of shares at the IPO price less discounts.

15-07-2026

Churchill Capital Corp XIII, a blank-check company, filed an S-1 registration statement on July 15, 2026, for its initial public offering. The filing details the proposed offering of units consisting of ordinary shares and warrants, with various redemption scenarios and the potential exercise of an over-allotment option. The company has no prior operating history and will use the proceeds to search for a target business combination.

• · The filing is an S-1 registration statement under the Securities Act of 1933.
• · The SEC file number is 333-297472.
• · The company is incorporated in the state of E9 (likely Delaware).
• · The fiscal year end is December 31.
• · The business address is 640 Fifth Avenue, 12th Floor, New York, NY 10019.
• · The filing includes detailed per-share data tables for various redemption scenarios (0%, 25%, 50%, 75%, 100%) and with/without over-allotment option.
• · The company is a non-accelerated filer and an affiliate of the sponsor.
• · The filing date is July 15, 2026, and the document was filed at 14:30:20.

15-07-2026

authID Inc. filed an S-1 registration statement to register up to 4,637,852 shares of common stock for resale by selling stockholders, consisting of 4,065,000 warrant shares and 572,852 fee shares from an April 2026 private placement. The company has substantial doubt about its ability to continue as a going concern, with an accumulated deficit of approximately $196.2 million, cash of only $1.2 million as of March 31, 2026, and a net loss from operations of $4.5 million in Q1 2026. While the April 2026 offering raised about $3.5 million in net proceeds, the company's revenue was only $0.5 million in the quarter and it used $3.4 million in operating cash, highlighting severe financial strain.

• · The April 2026 Debentures are senior secured obligations maturing in October 2026, bear no interest, and are secured by a first-priority security interest in substantially all company assets.
• · The April 2026 Warrants have an exercise price of $1.50 per share, a five-year term, and include a cashless exercise provision and beneficial ownership limitation of 4.99% or 9.99% (19.99% for one director).
• · Fee Shares equal 15% of the principal amount invested divided by $1.00 (or Nasdaq closing bid price for a director).
• · The registration is subject to Nasdaq's 19.99% limitation under Listing Rule 5635, requiring stockholder approval for any excess.
• · The company changed its name from Ipsidy Inc. to authID Inc. on July 18, 2022.
• · The company's common stock trades on Nasdaq Capital Market under symbol 'AUID'.

15-07-2026

Sono Group N.V. filed an S-4 registration statement on July 15, 2026, proposing a redomiciliation transaction from the Netherlands to Delaware via Luxembourg. The transaction involves a cross-border merger of Sono N.V. into a Luxembourg subsidiary, followed by a conversion into a Delaware corporation named Sono Group, Inc. The Management Board and Supervisory Board unanimously recommend shareholders vote 'FOR' the proposals at the extraordinary general meeting. However, the filing notes uncertainty about meeting Nasdaq continued listing requirements, and the stock price declined from $3.93 on July 14, 2026, to an undisclosed lower level as of the latest practicable date.

• · The redomiciliation is structured in two steps due to Dutch law restrictions: first a merger into a Luxembourg entity, then conversion to a Delaware corporation.
• · Share exchange ratios are designed to preserve voting and economic interests: each Sono N.V. Ordinary Share becomes one share of Class A Common Stock; each High Voting Share (25 votes) becomes 25 LuxCo Class B Ordinary Shares (each 1 vote), then 1 share of Class B Common Stock; each Preferred Share becomes 30,000 LuxCo Preferred Shares, then 1 share of Series A Preferred Stock.
• · The filing includes a Nasdaq Share Authorization Proposal to allow issuance of 20% or more of common shares or voting power at below Minimum Price without a public offering.
• · The stock price on the latest practicable date before the proxy statement was not disclosed, but was lower than $3.93.
• · The company expects the Class A Common Stock to continue trading under the same ticker symbol on Nasdaq-CM, but there is no assurance of continued listing.

15-07-2026

Rallybio Corp filed an S-4 registration statement on July 15, 2026, in connection with a proposed merger with Candid Therapeutics. The filing includes financial statements for the years ended December 31, 2025 and 2024, and quarterly periods through March 31, 2026. The company has no revenue and has incurred significant net losses, with research and development expenses increasing from $29.5M in 2024 to $37.2M in 2025, while general and administrative expenses decreased from $17.8M to $14.5M over the same period.

• · The merger agreement with Candid Therapeutics was entered into on March 1, 2026.
• · Cash and cash equivalents were $41.9M as of December 31, 2025, and $28.5M as of March 31, 2026.
• · Net loss for 2025 was $52.3M compared to $47.5M in 2024.
• · The company has an accumulated deficit of $347.8M as of December 31, 2025.